Coronavirus (COVID-19) Information For Medicare Advantage Providers

The COVID-19 Public Health Emergency (PHE) ended May 11, 2023. Coverage and benefit information for Aspirus Health Plan members is outlined in this update and replaces any previous COVID-19 content.

Contact the Provider Assistance Center at 715.631.7412 or 1.855.931.4851 with any questions.

DOCUMENT LAST UPDATED MARCH 13, 2024

COVID-19
Billing and Payment

Telehealth Services

Additional billing and payment information about telehealth services is available on the [Telehealth, Telemedicine and Technology Based Services](#) page.

COVID-19 Tests and Treatment

Over-the-Counter COVID-19 Tests

The federal Medicare program no longer covers OTC COVID-19 tests. After May 11, 2023 (the end of the Public Health Emergency), Aspirus Health Plan members can use their Aspirus Health Plan Healthy Benefits+ Visa® card to purchase OTC COVID-19 tests.

COVID-19 Vaccines

COVID-19 vaccines are covered with no cost share as a preventive service for all Aspirus Health Plan products.

Monoclonal Antibodies

Aspirus Health Plan covers monoclonal antibody treatments that have emergency use authorization or are authorized by the FDA. Treatments for COVID-19 are continually changing. COVID-19 monoclonal antibodies can be used for all Aspirus Health Plan products.

Member Out-of-Pocket Expenses: COVID-19-Related Coverage

After May 11, 2023 (the end of the Public Health Emergency), any hospital deductibles, copays, or coinsurance will be applied for inpatient, observation, outpatient, office-based clinic and emergency department services.

COVID-19

Telehealth, Telemedicine and Technology Based Services

Telehealth, Telemedicine and Technology-Based Services

For updated telehealth, telehealth, telemedicine and technology-based service coding and billing and information on or after May 12, 2023, refer to:

Medicare Products

https://www.cms.gov/files/document/mln901705-telehealth-services.pdf

Medicare Claims Processing Manual, Section 190